Heart Failure

New research from ACC.20/WCC suggests taking statins before initiating chemotherapy with anthracycline or trastuzumab could reduce treatment-associated cardiotoxicity.

A study from EPI Scientific Sessions 2020 is shedding light on the prevalence of certain risk factors among black ethnic groups compared to their white counterparts.

A Mayo Clinic analysis is shedding light on the real-world success of ablation in lowering risk of mortality and HF hospitalizations.

The approval allows Zynex to market CM-1500, a blood monitoring system aimed at helping doctors monitor various patient parameters.

Results of the LINK-HF study indicate a wearable sensors from Vital Connect combined with a predictive algorithm can predict HF exacerbations.

A look back on the biggest discussions of the 29th Annual Cardiovascular Conference in Beaver Creek, CO.

A fourth-year medical student offers perspective on a study examining machine learning models being presented at CCC 49 in Orlando, FL as part of HCPLive's Notes from Rounds program.

Findings of a recent study may help providers make more informed treatment recommendations for patients with reduced blood flow.

Results of an analysis incorporating data on more than 29,000 patients concluded consuming 2 or more servings of meat per week increased risk of cardiovascular disease.

A meta-analysis of CREDENCE, DECLARE-TIMI 58, CANVAS, and EMPA-REG OUTCOME trial is revealing more about how SGLT2 inhibition impacts different subgroups of diabetics.

An analysis of the Southern Community Cohort Study found differences in the impact of modifiable risk factors for heart failure among black and white patients.

An oral tablet combining empagliflozin, linagliptin, metformin hydrochloride will soon be available on US markets.

New data from the Annual Meeting of the Society of Thoracic Surgeons reveals a three-day stay is not associated with increased risk of worse outcomes or readmission.

A new analysis of more than 125,000 found no differences in mortality or MACE based on type of insulin used.

New data suggests sacubitril/valsartan could reduce risk of hospitalization and mortality in HFrEF patients when compared with ACEs/ARBs.

A new review in the Journal of the American College of Cardiology is highlighting the impact of marijuana use on heart health.

New research suggests Abbott's HeartMate 3 could revolutionize preimplantation strategy by eliminating use of categories based on transplant eligibility.

Less than 1 in 4 eligible Medicare patients attend a cardiac rehabilitation program and, among participants, adherence to programs remains an issue.

An analysis of more than 9000 patients found incident heart disease was associated with an increased risk of developing kidney failure later in life.

A recent study found a lower blood pressure target in older adults could reduce risk of cardiovascular events and death, but could negatively impact kidney function.

Abbot announced early Tuesday morning that the US FDA has granted approval for the HeartMate 3 device to be implanted via a lateral thoracotomy for patients with advanced heart failure.

A study from investigators at UCLA has identified a biomarker investigators suggest can help identify stable heart failure patients at an increased risk of death within the next 3 years.

Increased levels of pyrethroid insecticide exposure was linked to increased in all-cause mortality, as well as increases in mortality from cancer and cardiovascular disease in a recent study from the University of Iowa.

A recent study from the Mayo Clinic of Rochester, MN is suggested diabetes mellitus is an independent risk factor for the development of heart failure.

How the two critical specialties become better bridged at medical meetings?